Current guidance
48 items
Each item compared with the same item in the previous release (May 5, 2026). Values in quotation marks are the company’s words.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Net sales | for Q3 FY2026 | — | “$3,120 - $3,220” | Filing ↗ |
| Lowered | Net sales | for FY2026 | “$12,800 - $13,200” | “$12,600 - $12,800” | Filing ↗ |
| New | Adjusted EBITDA | for Q3 FY2026 | — | “$545 - $575” | Filing ↗ |
| Lowered | Adjusted EBITDA | for FY2026 | “$2,360 - $2,480” | “$2,310 - $2,370” | Filing ↗ |
| New | Adjusted EBITDA margin | for Q3 FY2026 | — | “17.7%” | Filing ↗ |
| Lowered | Adjusted EBITDA margin | for FY2026 | “18.6%” | “18.4%” | Filing ↗ |
| New | Adjusted net income per share | for Q3 FY2026 | — | “$1.25 - $1.35” | Filing ↗ |
| Lowered | Adjusted net income per share | for FY2026 | “$5.70 - $6.10” | “$5.60 - $5.80” | Filing ↗ |
| New | U.S. GAAP diluted net income per share from continuing operations | for Q3 FY2026 | — | “$0.86 - $0.96” | Filing ↗ |
| New | U.S. GAAP diluted net income per share from continuing operations | for FY2026 | — | “$4.06 - $4.26” | Filing ↗ |
| New | U.S. GAAP net income from continuing operations | for Q3 FY2026 | — | “$180 - $200” | Filing ↗ |
| New | U.S. GAAP net income from continuing operations | for FY2026 | — | “$860 - $900” | Filing ↗ |
| New | U.S. GAAP net income from continuing operations margin | for Q3 FY2026 | — | “6.0%” | Filing ↗ |
| New | U.S. GAAP net income from continuing operations margin | for FY2026 | — | “6.9%” | Filing ↗ |
| New | Adjusted effective tax rate | for FY2026 | — | “~18%” | Filing ↗ |
| New | Cash flow from continuing operations | for FY2026 | — | “$1,270 - $1,370” | Filing ↗ |
| Lowered | Free cash flow | for FY2026 | “$650 - $850” | “$625 - $725” | Filing ↗ |
| New | U.S. GAAP effective tax rate | for FY2026 | — | “~18%” | Filing ↗ |
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Net sales (Total Aptiv) | for FY2026 | “$21,120 - $21,820” | — | Filing ↗ |
| Not restated | Net sales (Versigent Pro Forma) | for FY2026 | “$9,100 - $9,400” | — | Filing ↗ |
| Not restated | Adjusted EBITDA (New Aptiv Pro Forma) | for FY2026 | “$2,360 - $2,480” | — | Filing ↗ |
| Not restated | Adjusted EBITDA (Total Aptiv) | for FY2026 | “$3,385 - $3,585” | — | Filing ↗ |
| Not restated | Adjusted EBITDA (Versigent Pro Forma) | for FY2026 | “$950 - $1,030” | — | Filing ↗ |
| Not restated | Adjusted EBITDA margin (New Aptiv Pro Forma) | for FY2026 | “18.6%” | — | Filing ↗ |
| Not restated | Adjusted EBITDA margin (Total Aptiv) | for FY2026 | “16.2%” | — | Filing ↗ |
| Not restated | Adjusted EBITDA margin (Versigent Pro Forma) | for FY2026 | “10.7%” | — | Filing ↗ |
| Not restated | Adjusted net income per share (Total Aptiv) | for FY2026 | “$8.15 - $8.75” | — | Filing ↗ |
| Not restated | U.S. GAAP diluted net income per share | for FY2026 | “$3.85 - $4.25” | — | Filing ↗ |
| Not restated | U.S. GAAP diluted net income per share (New Aptiv Pro Forma) | for FY2026 | “$3.85 - $4.25” | — | Filing ↗ |
| Not restated | U.S. GAAP diluted net income per share (Total Aptiv) | for FY2026 | “$5.75 - $6.35” | — | Filing ↗ |
| Not restated | U.S. GAAP net income | for FY2026 | “$830 - $910” | — | Filing ↗ |
| Not restated | U.S. GAAP net income (New Aptiv Pro Forma) | for FY2026 | “$830 - $910” | — | Filing ↗ |
| Not restated | U.S. GAAP net income (Total Aptiv) | for FY2026 | “$1,235 - $1,365” | — | Filing ↗ |
| Not restated | U.S. GAAP net income (Versigent Pro Forma) | for FY2026 | “$315 - $375” | — | Filing ↗ |
| Not restated | U.S. GAAP net income margin | for FY2026 | “6.7%” | — | Filing ↗ |
| Not restated | U.S. GAAP net income margin (New Aptiv Pro Forma) | for FY2026 | “6.7%” | — | Filing ↗ |
| Not restated | U.S. GAAP net income margin (Total Aptiv) | for FY2026 | “6.1%” | — | Filing ↗ |
| Not restated | U.S. GAAP net income margin (Versigent Pro Forma) | for FY2026 | “3.7%” | — | Filing ↗ |
| Not restated | Cash flow from operations | for FY2026 | “$1,315 - $1,515” | — | Filing ↗ |
| Not restated | Cash flow from operations (New Aptiv Pro Forma) | for FY2026 | “$440 - $540” | — | Filing ↗ |
| Not restated | Cash flow from operations (Total Aptiv) | for FY2026 | “$1,315 - $1,515” | — | Filing ↗ |
| Not restated | Free cash flow (Total Aptiv) | for FY2026 | “$650 - $850” | — | Filing ↗ |
| Not restated | U.S. GAAP effective tax rate (Total Aptiv) | for FY2026 | “~20.5%” | — | Filing ↗ |
| Not restated | Revenue growth (Aptiv) | No period stated | “mid-to-high single digit revenue growth” | — | Filing ↗ |
| Not restated | Adjusted EBITDA margins (Aptiv) | No period stated | “high-teens-to-low-twenties Adjusted EBITDA margins” | — | Filing ↗ |
| Not restated | U.S. GAAP operating income margins (Aptiv) | No period stated | “low-to-mid teens U.S. GAAP operating income margins” | — | Filing ↗ |
| Not restated | Free cash flow (Aptiv) | No period stated | “significant free cash flow” | — | Filing ↗ |
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Net sales | “$3,120 - $3,220” | for Q3 FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| Net sales | “$12,600 - $12,800” | for FY2026 | GAAP-tied | Feb 2, 2026 | 3 | Filing ↗ |
| Net sales (New Aptiv Pro Forma) | “$12,800 - $13,200” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Net sales (Total Aptiv) | “$21,120 - $21,820” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Net sales (Versigent Pro Forma) | “$9,100 - $9,400” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$545 - $575” | for Q3 FY2026 | Company-defined | Aug 4, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA | “$2,310 - $2,370” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Adjusted EBITDA (New Aptiv Pro Forma) | “$2,360 - $2,480” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA (Total Aptiv) | “$3,385 - $3,585” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA (Versigent Pro Forma) | “$950 - $1,030” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA margin | “17.7%” | for Q3 FY2026 | Company-defined | Aug 4, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA margin | “18.4%” | for FY2026 | Company-defined | Feb 2, 2026 | 3 | Filing ↗ |
| Adjusted EBITDA margin (New Aptiv Pro Forma) | “18.6%” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA margin (Total Aptiv) | “16.2%” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA margin (Versigent Pro Forma) | “10.7%” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted net income per share | “$1.25 - $1.35” | for Q3 FY2026 | Company-defined | Aug 4, 2026 | 1 | Filing ↗ |
| Adjusted net income per share | “$5.60 - $5.80” | for FY2026 | Company-defined | May 5, 2026 | 2 | Filing ↗ |
| Adjusted net income per share (New Aptiv Pro Forma) | “$5.70 - $6.10” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted net income per share (Total Aptiv) | “$8.15 - $8.75” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP diluted net income per share | “$3.85 - $4.25” | for FY2026 | GAAP-tied | May 5, 2026 | 1 | Filing ↗ |
| U.S. GAAP diluted net income per share (New Aptiv Pro Forma) | “$3.85 - $4.25” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP diluted net income per share (Total Aptiv) | “$5.75 - $6.35” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP diluted net income per share from continuing operations | “$0.86 - $0.96” | for Q3 FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP diluted net income per share from continuing operations | “$4.06 - $4.26” | for FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income | “$830 - $910” | for FY2026 | GAAP-tied | May 5, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income (New Aptiv Pro Forma) | “$830 - $910” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income (Total Aptiv) | “$1,235 - $1,365” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income (Versigent Pro Forma) | “$315 - $375” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income from continuing operations | “$180 - $200” | for Q3 FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income from continuing operations | “$860 - $900” | for FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income from continuing operations margin | “6.0%” | for Q3 FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income from continuing operations margin | “6.9%” | for FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income margin | “6.7%” | for FY2026 | GAAP-tied | May 5, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income margin (New Aptiv Pro Forma) | “6.7%” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income margin (Total Aptiv) | “6.1%” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP net income margin (Versigent Pro Forma) | “3.7%” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Adjusted effective tax rate | “~18%” | for FY2026 | Company-defined | Aug 4, 2026 | 1 | Filing ↗ |
| Cash flow from continuing operations | “$1,270 - $1,370” | for FY2026 | Company-defined | Aug 4, 2026 | 1 | Filing ↗ |
| Cash flow from operations | “$1,315 - $1,515” | for FY2026 | GAAP-tied | May 5, 2026 | 1 | Filing ↗ |
| Cash flow from operations (New Aptiv Pro Forma) | “$440 - $540” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Cash flow from operations (Total Aptiv) | “$1,315 - $1,515” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Free cash flow | “$625 - $725” | for FY2026 | Company-defined | May 5, 2026 | 2 | Filing ↗ |
| Free cash flow (Total Aptiv) | “$650 - $850” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Free cash flow (Versigent Pro Forma) | “$200 - $300” | for FY2026 | Company-defined | Feb 2, 2026 | 1 | Filing ↗ |
| Separation transaction completion target | “completion of the separation by March 31, 2026” | for FY2026 | Company-defined | Jan 22, 2025 | 1 | Filing ↗ |
| U.S. GAAP effective tax rate | “~18%” | for FY2026 | GAAP-tied | Aug 4, 2026 | 1 | Filing ↗ |
| U.S. GAAP effective tax rate (New Aptiv Pro Forma) | “~18.5%” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| U.S. GAAP effective tax rate (Total Aptiv) | “~20.5%” | for FY2026 | GAAP-tied | Feb 2, 2026 | 1 | Filing ↗ |
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Share repurchases as a portion of expected cash flow | “half” | — | Declared action | Aug 4, 2026 | 1 | Filing ↗ |
Net sales, for FY2025 — every statement across the year, each linked to its filing.
12 companies in Autos & components. What they guide on, and who reported this season.
| General Motors | Oct 20, 2026 | 6 changes |
| Ford Motor | Oct 2, 2026 | 0 changes |
| Dana | Aug 6, 2026 | 10 changes |
| BorgWarner | Aug 5, 2026 | 13 changes |
| Goodyear Tire & Rubber | Aug 5, 2026 | 6 changes |
| Aptiv | Aug 4, 2026 | 18 changes |
| Allison Transmission | Aug 3, 2026 | 11 changes |
| Lear | Jul 31, 2026 | 5 changes |
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|
| Net sales | 7 statements | 6 statements | 1 statement | — |
| Net sales (New Aptiv Pro Forma) | 2 statements | — | — | — |
| Revenue growth (Aptiv) | — | — | — | 1 statement |
| Wind River revenue growth | — | 1 statement | — | — |
| Adjusted EBITDA | 7 statements | 6 statements | 1 statement | — |
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 4, 2026 | FY2026 Q2 | 0001521332-26-000057 | 19 | Open filing ↗ |
| May 5, 2026 | FY2026 Q1 | 0001521332-26-000044 | 18 | Open filing ↗ |
| Feb 2, 2026 | FY2025 Q4 | 0001521332-26-000004 | 37 | Open filing ↗ |
| Oct 30, 2025 | FY2025 Q3 | 0001521332-25-000048 | 27 | Open filing ↗ |
| Jul 31, 2025 | FY2025 Q2 | 0001521332-25-000036 | 27 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0001521332-25-000023 | 27 | Open filing ↗ |
| Jan 22, 2025 | FY2024 Q4 | 0001521332-25-000003 | 5 | Open filing ↗ |
| Oct 31, 2024 | FY2024 Q3 | 0001521332-24-000067 | 16 | Open filing ↗ |
2 values were detected in these releases but could not be matched to an exact sentence in the filing body, so they are not shown as guidance. We surface the count rather than drop it silently.
| Span | Why | Filed |
|---|---|---|
| Motional equity losses impact on diluted EPS guidance = approximately $0.20 | span gate: value not verbatim in filing | Jul 31, 2025 |
| Anticipated equity losses from Motional autonomous driving joint venture included in guidance (per diluted share) = approximately $0.30 | span gate: value not verbatim in filing | May 1, 2025 |